Klaus Pantel

Current position : Director of Institute of Tumor Biology, Full Professor (C4) of Medicine, University Hospital Eppendorf (UKE), University of Hamburg, Germany

Academic education and graduation :

05/1983 - 05/1987              University of Cologne, Medical Clinic I, Germany. Thesis: Mathematical Modeling in Hematopoiesis, Degree: Dr. med.

04/1980 – 05/1986             Study of Human Medicine, University of Cologne, School of Medicine, Germany. Degree: M.D.

Academic degrees :

05/1989 - 06/1995              Dr. med. habil. (“Associate Professor”), Medical Department of the Ludwig-Maximilians-Universität Munich, Institute of Immunology,

                                          Subject: Immunology (Immunocytochemical and molecular analyses on the diagnosis, clinical relevance and pathophysiology of minimal

                                                                              residual disease in cancer patients)

1987                                  Dr. med., University of Cologne Subject: Mathematical Modeling in Hematopoiesis

since 2015                         Member of the Executive Board of the University Cancer Center

since 06/2002                    Hamburg – Hubertus Wald Tumor Center Director of the new Institute of Tumor Biology, Full Professor (C4) of Medicine,

                                          University Hospital Eppendorf (UKE), University of Hamburg, Germany

since 2002                         Coordinator of the Oncology Research Program at UKE

09/2002 - 08/2008             Deputy Director of the new Center of Experimental Medicine, UKE

01/1999 - 05/2002             Professor (C3) in Molecular Genetics, Department of Gynecology and Obstetrics,

                                         University Hospital Eppendorf, University of Hamburg, Germany

                                         Head of Molecular Oncology, Department of Gynecology and Obstetrics, University Hospital Eppendorf, University of Hamburg, Germany

07/1995 – 12/1998             Associate Professor (“Privatdozent”), Institute of Immunology, LudwigMaximilians-University, Munich, Germany

06/1989 – 12/1998             Research Scientist, Head, Micrometastasis Research Laboratory, Institute for Immunology,

                                            Ludwig-Maximilians-University, Munich, Germany

                                         Head, Project Group “Early metastasis of epithelial tumours”, Tumor Centre Munich, Germany Scientific Head of the Animal Care Unit,

                                           Institute of Immunology

05/1987 – 05/1989             Postdoctoral DFG-Fellow , Research Associate, Division of Hematology and Oncology, Department of Internal Medicine,

                                            Wayne State University School of Medicine, Detroit, MI, USA

06/1986 – 04/1987             Research Associate, Department of Biostatistics, Medical Institute of Environmental Hygiene, Düsseldorf, Germany

Editorial and Publishing Activities :

                                          British Journal of Cancer, Journal of Epithelial Biology and Pharmacology, Current

                                          Cancer Therapy Reviews, Journal of Translational Medicine, Cancer Research and

                                          Clinical Oncology, TumorDiagnostik & Therapie, Clinical & Experimental Metastasis,

                                          Cancer Research, Clinical Cancer Research, Molecular Oncology, Cancers, Breast Cancer Research, EORTC Translational Research

Selected Professional Memberships :

since 2016                         Member of the European Academy for Tumor Immunology

since 2010                         Member of The New York Academy of Sciences

since 2007                         Member of the Metastasis Research Society

since 1991                         Member of the American Association for Cancer Research

since 1991                         Member of the German Cancer Society

since 1990                         Member of the German Societies for Immunology, Cell Biology, Hematology and Oncology

2011                                  Award of the Breast Cancer Survivor Group “mamazone” 2011, Augsburg

2011                                 ERC (European Research Counsil) Advanced Investigators Grant

2010                                 AACR Outstanding Investigator Award for Breast Cancer Research, San Antonio

2010                                 German Cancer Award 2010 (Translational Area), German Cancer Society, Berlin

2009                                 AIO Medical Oncology Scientific Award 2008, Berlin

2009                                 Wilhelm-Warner Award for Cancer Research 2008, Hamburg

2005                                 C. G. Schmidt Award for Cancer Research, Essen

2001                                Brompton-Award of the European Society of Thoracic Surgeons

1998                                Walter-Schulz Fund Award, Munich

1997                                Publication Award of the Scientific Committee of the European Society of Thoracic Surgeons

1996                                Georg-Ernst-Konjetzny Award of the Hamburger Krebsgesellschaft together with S. Hosch & J.R. Izbicki

1995                                Award of the Johann-Georg-Zimmermann Fund, Hannover together with G. Schaller

                                       Publication Award 1995 of the German Society of Thoracic Surgeons together with B. Passlick, Senior author: K. Pantel

1994                                Georg-Ernst-Konjetzny-Award of the Hamburg Cancer Society together with B. Passlick, J.R. Izbicki, G. Riethmüller

1992                                Gerhard-Domagk Award for Clinical and Experimental Cancer Research, Münster together with G. Riethmüller, I. Funke, G. Schlimok.

1990                                ISEH New Investigator Award, International Society for Experimental Hematology, 19th Annual Meeting, Seattle, WA, USA.

1988                                Postdoctoral Fellow of the German Research Foundation (“Deutsche Forschungsgemeinschaft”)

1987                                Research stipend of the Dr. Mildred Scheel Foundation/German Cancer Aid Fund

Scientific coordinator of the following projects :

                CANCER-ID IMI EU, 01/2015-12/2019, 60 calender months EU Innovative Medicines Joint Undertaking (IMI JU) Call

"Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood”, more than 32 European partners

                 LIQUOPSY, 05/2014-04/2016, 24 calender months EU/BMBF (Federal Ministry of Education and Research)

"Liquid biopsy: In vivo capturing and molecular characterization of circulating tumor cells as a novel tool for improving tertiary prevention in breast cancer”, 3 European partners

                 TRANSCAN ERA-Network 06/2013-05/2016, 36 calender months EU/BMBF (Federal Ministry of Education and Research)

"Circulating Tumor Cells as Biomarker for Minimal Residual Disease in Prostate Cancer", CTC-SCAN, 6 European partners

PI of the following projects (selection) :

DFG 1/2016-12/2019, 36 calendar months, PA 341/19-2

      “Functional characterization of the putative metastasis suppressor protein RAI2”

CAPTURE-CTC, 2015-2016, 18 calendar months

HORIZON 2020 ERC-PoC 66546

     “A Streptavidin Microarray Platform for Capturing of Circulating Tumor Cells from the Blood of Cancer Patients”

DISSECT, 8/2011-7/2016, 60 calendar months

ERC Advanced Investigator Grant ERC-2010-AsG_20100317

     “Disseminating tumor cells as novel biomarkers: Dissecting the metastatic cascade in cancer patients”

Organization of International Meetings and Workshops:

1996 – 2016           1st - 10th International Symposium on Minimal Residual Cancer, Paris, Osaka, Athens, Hamburg, San Francisco, Oslo, Berlin, Munich

2006                      Workshop on Tumor Cell Dormancy, NIH, Bethesda, USA

Management :

1994           Co-founder of Micromet GmbH, Martinsried, Germany

2002           Founder, Institute of Tumor Biology, UKE, Hamburg

Patents

• EPO patent registration No. EP2561089 “Method of determining the metastatic potential of a tumor”

• EPO patent registration No. 95108760.7 “Immortalized epithelial cells”

• EPO patent application No. 07825055.2 “Released cytokeratins as markers for epithelial cells”

• EPO patent application No. 10004180.5 “Method of determining the metastatic potential of a tumor”

Selected Publications :

More than 400 publications, h-index: 74

• Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nature Rev. Cancer 2014;14: 623-31.

• Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Caranana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K*, Pierga JY*, Michiels S*. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15: 406-14. (*shared senior authorship)

• Muller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, Matschke J, Langer-Freitag S, Gasch C, Stoupiec M, Mauermann O, Peine S, Glatzel M, Speicher MR, Geigl JB, Westphal M, Pantel K*, Riethdorf S. Hematogenous dissemination of glioblastoma multiforme. Sci. Transl. Med. 2014;6: 247ra101. (*shared senior authorship)

• Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, Nishida N, Kogo R, Sudo T, Tanaka F, Shibata K, Toh H, Sato T, Barnard GF, Fukagawa T, Yamamoto S, Nakanishi H, Sasaki S, Miyano S, Watanabe T, Kuwano H, Mimori K, Pantel K*, Mori M. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 2013;73: 2059-69 (*shared senior authorship).

• Pantel K, Diaz LA, Jr., Polyak K. Tracking tumor resistance using 'liquid biopsies'. Nat. Med. 2013;19: 676- 7.

• Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013;23: 573-81.

• Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc. Natl. Acad. Sci. U. S. A. 2011;108: 12396-400.

• Kollermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T, Pantel K. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J. Clin. Oncol. 2008;26: 4928-33.

• Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 2008;8: 329-40.

• Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005;353: 793-802.

• Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, Pichlmeier U, Schlimok G, Oberneder R, Kollermann MW, Kollermann J, Speicher MR, Pantel K. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc. Natl. Acad. Sci. U. S. A. 2002;99: 2246-51.

• Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 2000;342: 525-33.

• Pantel K, Passlick B, Vogt J, Stosiek P, Angstwurm M, Seen-Hibler R, Haussinger K, Thetter O, Izbicki JR, Riethmuller G. Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J. Clin. Oncol. 1998;16: 1407-13.

• Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, Pantel K. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N. Engl. J. Med. 1997;337: 1188-94.

• Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, Riethmuller G. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996;347: 649-53.